HD15 for advanced stage Hodgkin's disease: Quality assurance protocol for reduction of toxicity and the prognostic relevance of fluorodeoxyglucose-positron-emission tomography (FDG-PET) in the first-line treatment of advanced stage Hodgkin's disease

ISRCTN ISRCTN32443041
DOI https://doi.org/10.1186/ISRCTN32443041
Secondary identifying numbers N/A
Submission date
11/09/2003
Registration date
29/10/2003
Last edited
07/10/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Volker Diehl
Scientific

German Hodgkin's Lymphoma Study Group
Herderstr. 52-54
Cologne
50924
Germany

Phone +49/221/478-3557 (-3558)
Email dhsg@biometrie.uni-koeln.de

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Patient information sheet can be found at http://www.lymphome.de/en/Groups/GHSG/Protocols/HD15/Patient-Information.pdf
Scientific title
Study acronymHD15
Study objectivesPrimary aim:
Reduction of toxicity, de-escalation of chemotherapy while maintaining high freedom from treatment failure (FFTF) and overall survival (OS) rates.

Secondary aims:
Assess the influence of erythropoietin on the quality of life and the effect of FDG-PET on prognosis.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedHodgkin's disease
InterventionIn this trial three combinations of chemotherapy are compared in a randomised, controlled trial (open-label). In addition patients in every arm are randomly assigned to receive erythropoetin or placebo (double-blind). Restaging with PET is not allocated in a randomised fashion:

Arm A:
1. 8 x erythropoietin, cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine (BEACOPP) (escalated)
2. Erythropoetin/placebo
3. 30 Gy involved field radiotherapy if partial remission after chemotherapy and PET is positive

Arm B:
1. 6 x BEACOPP (escalated)
2. Erythropoetin/placebo
3. 30 Gy involved field radiotherapy if partial remission after chemotherapy and PET is positive

Arm C:
1. 8 x BEACOPP-14
2. Erythropoetin/placebo
3. 30 Gy involved field radiotherapy if partial remission after chemotherapy and PET is positive
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Erythropoietin, cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine (BEACOPP)
Primary outcome measureFreedom from treatment failure (FFTF).
Secondary outcome measuresImpact of erythropoetin on quality of life and prognostic significance of FDG-PET.
Overall study start date01/01/2003
Completion date01/01/2008

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants400
Key inclusion criteriaChemotherapy:
1. Histologically confirmed Hodgkin's disease
2. Stage IIB and massive mediastinal involvement (tumour one third or more of the maximum intrathoracic diameter) and/or extranodal involvement, stage III, and stage IV
3. No prior therapy for Hodgkin's disease
4. Age: 18 - 60 years
5. No major organ dysfunction
6. Life expectancy greater than 3 months
7. Written informed consent

PET:
1. Chemotherapy according to the HD15-protocol
2. Response to chemotherapy
3. Partial response with residual disease of at least 2.5 cm maximum diameter
Key exclusion criteriaChemotherapy:
1. Incomplete staging
2. Major organ dysfunction:
2.1. Chronic obstructive pulmonary disease (COPD) with respiratory insufficiency
2.2. Symptomatic coronary heart disease (CHD)
2.3. Cardiomyopathy or heart failure (ejection fraction less than 50%)
2.4. Severe hypertension
2.5. Non-treatable infections
2.6. White blood count less than 3000/mm^3 or platelets less than 100,000/mm^3 if not related to bone marrow involvement
2.7. Creatinine clearance less than 60 ml/min
2.8. Bilirubin greater than 2 mg/dl if not related to Hodgkin's disease
2.9. Glutamic oxaloacetic transaminase (GOT)/aspartate aminotransferase (AST) greater than 100 U/l if not related to Hodgkin's disease
2.10. Glutamic pyruvic transaminase (GPT)/alanine aminotransferase (ALT) greater than 100 U/l if not related to Hodgkin's disease
2.11. Human immunodeficiency virus (HIV)-infection
3. Composite lymphoma
4. Prior chemotherapy or radiotherapy
5. Any history of another malignancy in the last 5 years (except for cervical carcinoma in situ and fully resected melanoma TNMpT1)
6. Pregnancy or breastfeeding
7. World Health Organisation (WHO) performance status greater than 2
8. Long term use of corticosteroids (e.g. for arthritis) or antineoplastic substances (e.g. methotrexate)
9. Expected non-compliance
10. Current therapy for epilepsy
11. Intolerabilities against study drugs

PET:
1. Diabetes mellitus
2. Elevated blood glucose (greater than 130 mg/dl)
3. Massive bone involvement (endangering stability)
Date of first enrolment01/01/2003
Date of final enrolment01/01/2008

Locations

Countries of recruitment

  • Germany

Study participating centre

German Hodgkin's Lymphoma Study Group,
Cologne
50924
Germany

Sponsor information

German Hodgkin's Lymphoma Study Group (Germany)
Research organisation

Herderstr. 52-54
Cologne
50924
Germany

Phone +49 (0)221 478-3557 (-3558)
Email dhsg@biometrie.uni-koeln.de

Funders

Funder type

Charity

Deutsche Krebshilfe (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 15/11/2008 Yes No
Results article results 12/05/2012 Yes No
Results article results 10/06/2014 Yes No